Nexentis Technologies Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsNexentis Technologies Inc. is a Nevada-based biopharmaceutical and renewable energy holding company focused on oncology drug discovery through its wholly-owned MitoCareX subsidiary and solar projects through a joint venture.
What they do
The company operates through MitoCareX Bio Ltd., a drug discovery company developing therapeutics for cancer and inflammatory metabolic diseases by targeting the mitochondrial carrier family (SLC25A proteins). It also collaborates with Solterra Renewable Energy Ltd. in a 70%-owned joint venture (NITO Renewable Energy) for solar photovoltaic projects in Europe. The company recently divested its Save Foods agricultural business and NTWO OFF operations.
Revenue drivers
- MitoCareX (oncology therapeutics) — No revenue yet; it is a drug discovery platform with a focus on Non-Small Cell Lung Cancer (NSCLC) and pancreatic cancer.
- Solar joint venture (NITO Renewable Energy) — 70% interest in a joint venture with Solterra; no revenue yet; expects to sell renewable energy projects at various development stages.
- Services agreement with Voice Assist — Provides advisory and support services for deferred cash up to $1,000,000 cap and royalty considerations; minimal to no revenue so far.
Recent performance
Revenue has declined steadily from $232,274 in 2020 to $210,000 in 2025, with quarterly revenue in 2025 ranging from $2,000 to $140,000. The company reported net losses for every year from 2021 to 2025, with 2025 net loss of approximately $4.0 million. As of June 30, 2026, total assets were $18.7 million, total liabilities $16.9 million, and cash and equivalents $7.6 million. Shareholder equity was $1.9 million.
Strategy
Management is focused on advancing MitoCareX's oncology pipeline using its MITOLINE algorithm to discover and develop drug candidates targeting SLC25A transporters. The company is also pursuing solar projects in Europe through its joint venture, with plans to sell projects at various stages. It has divested non-core operations (Save Foods and NTWO OFF) to streamline focus. Acquisitions and joint ventures are key strategies, as seen with the MitoCareX acquisition and the Voice Assist services agreement.
Risks
- History of operating losses — The company has incurred losses every year since 2021 and expects additional losses, requiring significant additional capital.
- MitoCareX development risk — MitoCareX has limited operating history and no revenue; it may fail to successfully develop and commercialize its anti-cancer small molecule therapeutics or obtain regulatory approvals.
- Capital needs — The company may be unable to raise the additional capital required to fund MitoCareX's development programs on acceptable terms, which could force delays or termination.
- Acquisition and joint venture integration — The company may not successfully complete and integrate current or future acquisitions and joint ventures, which could disrupt business activities.
Outlook
Management intends to continue collaborating with Solterra to survey the European solar market for additional projects. For MitoCareX, the focus is on advancing early-stage pipeline programs and assessing efficacy on inflammatory metabolic diseases. The company expects to incur additional losses and will need to raise capital to fund operations and development.